NEW: This article and the downloadable list was updated on July 15th 2025 2022 – 2024 have been breakthrough years for AI in digital pathology. Many new startups, backed by lots of venture capital, as well as...
A strong suit of MIKAIA® is its wide portfolio of analysis apps for multiplexed immunofluorescence (mIF) / spatial proteomics. It can be used for both low-plex and high-plex panels and is compatbile with image formats...
This MIKAIA® app note demonstrates how to analyze a 47-plex spatial proteomics scan created with MACSima ™ (by Miltenyi Biotec), utilizing sequential immunofluorescence for the analysis: Instrument: MACSima™ by Miltenyi...
Researchers at the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) have developed PEDRA: Platform for Ex-Vivo Drug Response Assays. Up to 100 compounds are tested in parallel on primary patient...
The Laboratory for Bio-Micro Devices at Brigham and Women’s Hospital () develops drug releasing implantable intratumoral microdevices (IMD) [1]. Using MIKAIA®, they want to examine in a quantitative fashion how...
Welcome to our MIKAIA FAQs. We know that navigating a flexible digital pathology & spatial biology image analysis software like MIKAIA® can raise a lot of questions, and we’re here to help. Whether...
CODEX, now called PhenoCycler, by Akoya Biosciences, along with other sequential immunofluorescence technologies (e.g., Lunaphore (Comet), Miltenyi Biotech (MACSima), Leica Microsystems (Cell DIVE), or other vendors)...
We have contributed two article’s to this year’s Trillium Pathology issue. Here are the abstracts, with links to the full articles: V. Bruns, Programming-free Image-Analysis Workflows for IHC, IF and Spatial...